BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences.
Oppenheimer 33rd Annual Healthcare Conference:
| Location: | Virtual |
| Format: | Fireside chat and one-on-one meetings |
| Date: | March 13-15, 2023 |
| Fireside chat: | March 13, 10:00am ET |
| Presenter: | Spiro Rombotis |
| Webcast: | Link |
35th Annual Roth Conference:
| Location: | Dana Point, CA |
| Format: | Fireside chat and one-on-one meetings |
| Date: | March 12-14, 2023 |
| Fireside chat: | March 13, 3:00pm PT |
| Presenter: | Paul McBarron |
| Webcast: | Link |
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Contacts
| Company: | Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
| Investor Relations: | Irina Koffler, LifeSci Advisors, LLC, (646) 970-4681, ikoffler@lifesciadvisors.com |
© Copyright 2023 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
